BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter
Mike Rice, BioLife's Chairman and CEO, commented on the publication of theinaugural issue by stating, "We're very pleased to be able to share bestpractices, state-of-the-art techniques, and steps to optimize biopreservationpractices with participants in this field. We're looking forward to providingadditional informative and compelling content from guest authors in futureissues of BioPreservation Today."
BioLife's Scientific Advisory Board played a role in the development ofthe newsletter and SAB member Scott R. Burger, MD, founder of Advanced Cell &Gene Therapy, LLC, and a leading consultant to the industry, remarked on thepublication by stating, "I've been very impressed with the strides BioLife hasmade to position the company as a leading biopreservation tools provider.BioPreservation Today will be an effective vehicle to share relevant knowledgewithin the biopreservation field. Stability and yield of biological rawmaterial and cellular products, and cost per delivered dose, are criticalissues that BioLife clearly understands well, and can help hospital transplantlabs and commercial companies to overcome, via their products and consultingservices."
A downloadable version of the Winter 2009 issue of BioPreservation Todaycan be found here:http://www.biolifesolutions.com/docs/bpt/bptwinter09.pdf.
BioLife Solutions will be presenting and exhibiting at the PhacilitateCell & Gene Therapy Forum 2009, January 26-28 in Washington, DC(http://www.phacilitate.co.uk/pages/cgtherapy/index.html).
About BioLife Solutions, Inc.:
BioLife Solutions develops and markets patented hypothermicstorage/transport and cryopreservation media products for cells, tissues, andorgans. The Company's proprietary HypoThermosol(R) and CryoStor(TM) platformof biopreservation media products are marketed to academic researchinstitutions, hospitals, and commercial companies involved in cell therapy,tissue engineering, cord blood banking, drug discovery, and toxicologytesting. BioLife's GMP products are serum-free and protein-free, fullydefined, and pre-formulated to reduce preservation-induced, delayed-onset celldamage and death. Comprehensive small animal intravenous safety studies havebeen completed on HypoThermosol and CryoStor, and both products are supportedby US FDA Master Files. BioLife's enabling technology provides research andclinical organizations significantly enhanced in post-preservation cell andtissue viability and function.
For more information please visit http://www.biolifesolutions.com.
This news release contains forward-looking statements as that term isdefined in the Private Securities Litigation Reform Act of 1995. Theseforward-looking statements include any statements that relate to the intent,belief, plans or expectations of the Company or its management, or that arenot a statement of historical fact. Any forward-looking statements in thisnews release are based on current expectations and beliefs and are subject tonumerous risks and uncertainties that could cause actual results to differmaterially. Some of the specific factors that could cause BioLife Solutions'actual results to differ materially are discussed in the Company's recentfilings with the Securities and Exchange Commission. BioLife Solutionsdisclaims any obligation to update any forward-looking statements as a resultof developments occurring after the date of this press release.Media Relations: Len Hall Allen & Caron Inc. (949) 474-4300 email@example.com Investor Relations: Matt Clawson Allen & Caron Inc. (949) 474-4300 firstname.lastname@example.org
SOURCE BioLife Solutions, Inc.
You May Also Like